Prevention of Acute Graft-Versus-Host-Disease by Selective Depletion of T Cells Reactive with Minor Histocompatibility Antigens on Epithelial Cells

References

• Storb R, Deeg H J, Whitehead J, Appelbaum F, Beatty P, Bensinger W, Buckner C D, Clift R, Doney K, Farewell V, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729–35
   PubMed Web of Science ®Google Scholar
• Ringden O, Horowitz M M, Sondel P, Gale R P, Biggs J C, Champlin R E, Deeg H J, Dicke K, Masaoka T, Powles R L, et al. Methotrexate, Cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia?. Blood 1993; 81: 1094–1101
   PubMed Web of Science ®Google Scholar
• Rowlings P A, Przepiorka D, Klein J P, Gale R P, Passweg J R, Henslee-Downey P J, Cahn J Y, Calderwood S, Gratwohl A, Socie G, Abecasis M M, Sobocinski K A, Zhang M J, Horowitz M M. IBMTR severity index for grading acute graft-ver-sus-host disease: retrospective comparison with Glucksberg grade. British Journal of Haematology 1997; 97: 855–864
   PubMed Web of Science ®Google Scholar
• Atkinson K, Horowitz M M, Gale R P, van Bekkum D W, Gluckman E, Good R A, Jacobsen N, Kolb H J, Rimm A A, Ringden O, et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 1990; 75: 2459–2464
   PubMed Web of Science ®Google Scholar
• Atkinson K. Chronic graft-versus-host disease. Bone Marrow Transplantation 1990; 5: 69–82
   PubMed Web of Science ®Google Scholar
• Marmont A M, Horowitz M M, Gale R P, Sobocinski K, Ash R C, van Bekkum D W, Champlin R E, Dicke K A, Goldman J M, Good R A, et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991; 78: 2120–2130
   PubMed Web of Science ®Google Scholar
• Verdonck L F, Dekker A W, de Gast G C, van Kempen M L, Lokhorst H M, Nieuwenhuis H K. Allogeneic bone marrow transplantation with a fixed low number of T cells in the marrow graft. Blood 1994; 83: 3093–3096
   Google Scholar
• Weiden P L, Sullivan K M, Flournoy N, Storb R, Thomas E D. Antileukemic effect of chronic graft-versus-host disease, Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981; 304: 1529–1533
   PubMed Web of Science ®Google Scholar
• Horowitz M M, Gale R P, Sondel P M, Goldman J M, Kersey J, Kolb H J, Rimm A A, Ringden O, Rozman C, Speck B, Truitt R L, Zwaan F E, Bortin M M. Graft Versus Leukemia Reactions After Bone Marrow Transplantation. Blood 1990; 75: 555–562
   PubMed Web of Science ®Google Scholar
• McGlave P. Bone marrow transplants in chronic myelogenous leukemia: an overview of determinants of survival. Semin Hematol 1990; 27: 23–30
   PubMed Web of Science ®Google Scholar
• Goldman J M, Gale R P, Horowitz M M, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk for relapse associated with T cell depletion. Ann Intern Med 1988; 108: 806–814
   PubMed Web of Science ®Google Scholar
• Weiden P L, Flournoy N, Thomas E D, Prentice R, Fefer A, Buckner C D, Storb R. Antileukemia effect of graft ver-sus-host disease in human recipients of allogeneic marrow grafts. New Engl J Med 1979; 300: 1068–1073
   PubMed Web of Science ®Google Scholar
• Jones R J, Ambinder R F, Piantodosi S, Santos G W. Evidence of a graft versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991; 77: 649–65
   PubMed Web of Science ®Google Scholar
• Kolb H J, Schattenberg A, Goldman J M, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, van-Rhee Niederwieser D F, Mittermueller J, de-Witte T JM, Holler E, Ansari H. Graft versus-Leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041–2050
   PubMed Web of Science ®Google Scholar
• Mackinnon S, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft versus-leukemia from graft versus-host disease. Blood 1995; 86: 1261–1268
   PubMed Web of Science ®Google Scholar
• Falkenburg J HF, Smit W M, Willemze R. Cytotoxic T lymphocyte (CTL) responses against chronic or myeloid leukemia. Immunological Rev 1997; 157: 223–230
   PubMed Web of Science ®Google Scholar
• de-Bueger M, Bakker A, Bontkes H, van-Rood J J, Goulmy E. Bone-Marrow-Transplant. High frequencies of cytotoxic T cell precursors against minor histocompatibility antigens after HLA-identical BMT: absence of correlation with GVHD. Bone Marrow Transplant 1993; 11: 363–368
   PubMed Web of Science ®Google Scholar
• Fussell S T, Donnellan M, Cooley M A, Farrell C. Cytotoxic T lymphocyte precursor frequency does not correlate with either the incidence or severity of graft versus-host disease after matched unrelated donor bone marrow transplantation. Transplantation 1994; 57: 673–6
   PubMed Web of Science ®Google Scholar
• van Els C ACM, Bakker A, Zwinderman A, Zwaan F, van Rood J J, Goulmy E. Efector mechanisms in Graft ver-sus-Host disease in response to minor histocompatibility antigens. I. Absence of correlation with cytotoxic effector cells. Transplantation 1990; 50: 62–66
   PubMed Web of Science ®Google Scholar
• Liem A, van-Noort J T, Goulmy E. Anti-host cytotoxic T cells of bone marrow transplant recipients with or without graft versus-host disease are equally sensitive to cyclosporin. Bone Marrow Transplant 1996; 18: 73–78
   PubMed Web of Science ®Google Scholar
• de-Bueger M, Bakker A, van-Rood J J, van-der-Woude F, Goulmy E. Tissue distribution of human minor histocompatibility antigens. J Immunol 1992; 149: 1788–1794
   PubMed Web of Science ®Google Scholar
• Faber L M, van-Luxemburg-Heijs S A, Rijnbeek M, Willemze R, Falkenburg J H. Minor histocompatibility antigen-specific, leukemia-reactive cytotoxic T cell clones can be generated in vitro without in vivo priming using chronic myeloid leukemia cells as stimulators in the presence of alpha-interferon. Biol Blood Marrow Transplant 1996; 2: 31–36
   PubMedGoogle Scholar
• Dolstra H, Fredrix H, Preijers F, Goulmy E, Figdor C G, de-Witte T M, van-de-Wiel-van-Kemenade E. Recognition of a B cell leukemia-associated minor histocompatibility antigen by CTL. J Immunol 1997; 158: 560–565
   PubMed Web of Science ®Google Scholar
• van-Lochem E, van-der-Keur M, Mommaas A M, de-Gast G C, Goulmy E. Functional expression of minor histocompatibility antigens on human peripheral blood dendritic cells and epidermal Langerhans cells. Transpl Immunol 1996; 4: 151–157
   PubMedGoogle Scholar
• Mutis T, Schrama E, van-Luxemburg-Heijs S A, Falkenburg J H, Melief C J, Goulmy E. HLA class II restricted T cell reactivity to a developmentally regulated antigen shared by leukemic cells and CD34+ early progenitor cells. Blood 1997; 90: 1083–1090
   PubMed Web of Science ®Google Scholar
• Nishimura M, Akaza T, Mitomi Y, Nieda M, Minami M, Juji T. Establishment of human minor histocompatibility antigen-specific cytotoxic T cell clones restricted by HLA-DR9. Transplantation 1993; 55: 1181–1186
   PubMed Web of Science ®Google Scholar
• Vinci G, Masset M, Semana G, Vernant J PA. Human minor histocompatibility antigen which appears to segregate with the major histocompatibility complex. Transplantation 1994; 58: 361–367
   PubMed Web of Science ®Google Scholar
• Goulmy E, Gratama J W, Blokland E, Zwaan F E, van-Rood J J. A minor transplantation antigen detected by MHC-restricted cytotoxic T lymphocytes during graft versus-host disease. Nature 1983; 302: 159–161
   PubMed Web of Science ®Google Scholar
• Marijt W A, Kernan N A, Diaz-Barrientos T, Veenhof W F, O'Reilly R J, Willemze R, Falkenburg J H. Multiple minor histocompatibility antigen-specific cytotoxic T lymphocyte clones can be generated during graft rejection after HLA-identical bone marrow transplantation. Bone Marrow Transplant 1995; 16: 125–32
   PubMed Web of Science ®Google Scholar
• Faber L M, van-der-Hoeven J, Goulmy E, Hooftman-den-Otter A L, van-Luxemburg-Heijs S A, Willemze R, Falkenburg J H. Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes. J Clin Invest 1995; 96: 877–83
   PubMed Web of Science ®Google Scholar
• Warren E H, Greenberg P D, Riddell S R. Cytotoxic T lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution. Blood 1998; 91: 2197–207
   PubMed Web of Science ®Google Scholar
• Scott D M, Ehrmann I E, Ellis P S, Chandler P R, Simpson E. Why do some females reject males? The molecular basis for male-specific graft rejection. J Mol Med 1997; 75: 103–114
   PubMed Web of Science ®Google Scholar
• Goulmy E, Schipper R, Pool J, Blokland E, Falkenburg J H, Vossen J, Grathwohl A, Vogelsang G B, van-Houwelingen H C, van-Rood J J. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft versus-host disease after bone marrow transplantation. New Engl J Med 1996; 334: 281–285
   PubMed Web of Science ®Google Scholar
• den-Haan J M, Sherman N E, Blokland E, Huczko E, Koning F, Drijfhout J W, Skipper J, Shabanowitz J, Hunt D F, Engelhard V H, Goulmy E. Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science 1995; 268: 1476–80
   PubMed Web of Science ®Google Scholar
• Gubarev M I, Jenkin J C, Leppert M F, Buchanan G S, Otterud B E, Guilbert D A, Beatty P G. Localization to chromosome 22 of a gene encoding a human minor histocompatibility antigen. J Immunol 1996; 157: 5448–5454
   PubMed Web of Science ®Google Scholar
• den-Haan J M, Meadows L M, Wang W, Pool J, Blokland E, Bishop T L, Reinhardus C, Shabanowitz J, Offringa R, Hunt D F, Engelhard V H, Goulmy E. The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science 1998; 279: 1054–1057
   PubMed Web of Science ®Google Scholar
• Snover D C. Acute and chronic graft versus host disease: his-topathological evidence for two distinct pathogenetic mechansms. Human Pathol 1984; 15: 202–205
   PubMed Web of Science ®Google Scholar
• Bos J D, Kapsenberg M L. The skin immune system: progress in cutaneous biology. Immunology Today 1993; 14: 75–78
   PubMedGoogle Scholar
• Goulmy E, Gratama J W, Blokland E, Zwaan F E, van-Rood J J. A minor transplantation antigen detected by MHC-restricted cytotoxic T lymphocytes during graft versus-host disease. Nature 1983; 302: 159–161
   PubMed Web of Science ®Google Scholar
• Marijt W A, Kernan N A, Diaz-Barrientos T, Veenhof W F, O'Reilly R J, Willemze R, Falkenburg J H. Multiple minor histocompatibility antigen-specific cytotoxic T lymphocyte clones can be generated during graft rejection after HLA-identical bone marrow transplantation. Bone Marrow Transplant 1995; 16: 125–32
   PubMed Web of Science ®Google Scholar
• Bagot M, Cordonnier C, Tilkin A F, Heslan M, Vernant J P, Dubertret L, Levy J P. A possible predictive test for GVHD in bone marrow graft recipients: the mixed epidermal cell-lymphocyte reaction. Transplantation 1986; 41: 316–320
   PubMed Web of Science ®Google Scholar
• Vogelsang G B, Hess A D, Berkman A W, Tutschka P J, Farmer E R, Couverse P J, Santos G W. An in-vitro predictive test for GVHD in patients with genotypic HLA-identical bone marrow transplants. N Engl J Med 1985; 313: 645–650
   PubMed Web of Science ®Google Scholar
• Mutis T, de-Bueger M, Bakker A, Ottenhoff T H. HLA class II+ human keratinocytes present Mycobacterium leprae antigens to CD4+ Th1-like cells. Scand J Immunol 1993; 37: 43–51
   PubMed Web of Science ®Google Scholar
• Dickinson A M, Sviland L, Wang X N, Jackson G, Taylor P R, Dunn A, Proctor S J. Predicting graft-versus-host disease in HLA-identical bone marrow transplant: a comparison of T-cell frequency analysis and a human skin explant model. Transplantation 1998; 66: 857–63
   PubMed Web of Science ®Google Scholar
• de-Bueger M, Bakker A, Goulmy E. Human keratinocytes activate primed major and minor histocompatibility antigen specific Th cells in vitro. Transpl Immunol 1993; 1: 52–59
   PubMedGoogle Scholar
• Nickoloff B J, Mitra R S, Green J, Zheng X G, Shimizu Y, Thompson C, Turka L A. Accessory cell function of keratinocytes for superantigens. Dependence on lymphocyte function-associated antigen-1/intercellular adhesion molecule-1 interaction. J Immunol 1993; 150: 2148–2159
   PubMed Web of Science ®Google Scholar
• van-Dijk A MC, Otten H G, Vercauteren S M, Kessler F L, Verdonck L F, de-Boer M, de-Gast G C. Human B7–1 is more efficient than B7–2 in providing costimulation for allo-antigen specific T cells. Eur J Immunol 1996; 26: 2275–2278
   PubMed Web of Science ®Google Scholar
• van-Dijk A MC, Kessler F L, Verdonck L F, de-Gast G C, Otten H G. Selective depletion of alloantigen activated T cells: Towards prevention of acute graft-versus-host disease. Bj. J. Haematol 1999; 107: 169–175
   PubMed Web of Science ®Google Scholar
• Otten H G, Bor B, Ververs C, Verdonck L F, de-Boer M, de-Gast G C. Allo-antigen specific T cell anergy induced by human keratinocytes is abrogated upon loss of cell-cell contact. Immunology 1996; 88: 214–219
   PubMed Web of Science ®Google Scholar
• Otten H G, Van der Gouw Vooijs W CAP, De Boer M, Stirpe F, de Gast G C. Tissue antigens 1998; 52: 270–274, The effect of immunotoxins directed against CD80 and CD86 on primary T cell alloresponses
   PubMed Web of Science ®Google Scholar